Prevalence of chronic kidney disease in patients with various components of the metabolic syndrome requiring endovascular interventions, preliminary data from the Federal center: interim analysis

Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease and is a global burden with high economic costs for health systems. All stages of CKD are associated with an increased risk of cardiovascular events, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until the late stages, and accurate data on its prevalence are not available, including in the Russian Federation. In the medical literature, there are isolated works devoted to the study of the prevalence of CKD in patients with metabolic syndrome in a large population of patients, including those in need of various endovascular interventions that pose an additional risk of CKD progression. THE AIM: to study the prevalence of individual components of cardiorenometabolic syndrome depending on the presence of CKD in a sample of patients with cardiovascular disease planning endovascular intervention. PATIENT AND METHODS. The study included 9731 patients over 18 years of age, planning endovascular intervention. All patients were examined in accordance with Russian clinical guidelines. CKD C3a-C4 was diagnosed in 4378 patients. RESULTS. Patients with CKD were more likely to have diabetes mellitus, hypertension, atrial fibrillation and/or flutter, and CHF. Metabolic characteristics included higher body mass index, cholesterol, and CRP levels. CONCLUSION. Effective interdisciplinary collaboration between physicians of various specialties appears to be a key component of the management strategy for this patient population, with the aim of improving diagnostic and treatment algorithms and slowing the progression of cardiovascular disease and CKD.

1. Visseren FLJ, Mach F, Smulders YM et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42(34):3227–3237. doi: 10.1093/eurheartj/ehab484

2. Lavrishcheva YV, Konradi AO, Jakovenko AA, Rumyantsev AS. Biomarkers of acute post-contrast kidney injury in patients undergoing percutaneous coronary interventions. Nephrology (Saint-Petersburg) 2022;26(2):34–45. (In Russ.) doi: 10.36485/ 1561-6274-2022-26-2-34-45)

3. Matsushita K, Coresh J, Sang Y et al. CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative metaanalysis of individual participant data. Lancet Diabetes Endocrinol 2015;3(7):514–525. doi: 10.1016/S2213-8587(15)00040-6

4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382(9889):339–352. doi: 10.1016/S0140-6736(13)60595-4

5. Ndumele CE, Rangaswami J, Chow SL et al. on behalf of the American Heart Association. Cardiovascular-kidneymetabolic health: a presidential advisory from the American Heart Association. Circulation 2023;148(20):1606–1635. doi: 10.1161/CIR.0000000000001184

6. Ndumele CE, Neeland IJ, Tuttle KR et al. American Heart Association. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 2023;148(20):1636–1664. doi:10.1161/CIR.0000000000001186

7. Larkin H. Here's What to Know About Cardiovascular-Kidney-Metabolic Syndrome, Newly Defined by the AHA. JAMA 2023;330(21):2042–2043. doi: 10.1001/jama.2023.22276

8. Jakovenko AA, Esayn AM, Rumyantsev AS, Somova VM. The role of leptin in the pathogenesis of malnutrition in patients receiving chronic hemodialysis. Clinical Nephrology 2015;5–6:14–17. (In Russ.)

9. Rana MN, Neeland IJ. Adipose tissue inflammation and cardiovascular disease: an update. Curr Diab Rep 2022;22:27–37. doi: 10.1007/s11892-021-01446-9

10. Neeland IJ, Ross R, Despres JP et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7:715–725. doi: 10.1016/S2213-8587(19)30084-1

11. Wilson PW, D’Agostino RB, Parise H et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066–3072. doi: 10.1161/CIRCULATIONAHA.105.539528

12. Amdur RL, Feldman HI, Dominic EA et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis 2019;73:344–353. doi: 10.1053/j.ajkd.2018.09.012

13. Tuttle KR, Agarwal R, Alpers CE et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 2022;102:248–260. doi: 10.1016/j.kint.2022.05.012

14. Rangaswami J, Bhalla V, Blair JEA et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840–e878. doi: 10.1161 CIR.0000000000000664

15. Després JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28(6):1039–1049. doi: 10.1161/ATVBAHA.107.159228

16. Kontsevaya A, Shalnova S, Deev A et al. Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obes Facts 2019;12(1):103–114. doi: https://doi.org/10.1159/000493885

17. Salehidoost R, Mansouri A, Amini M et al. Diabetes and allcause mortality, a 18-year follow-up study. Sci Rep 2020;10(1):3183. doi:10.1038/s41598-020-60142-y

18. Turin TC, Tonelli M, Manns BJ et al. Chronic kidney disease and life expectancy. Nephrol Dial Transplant 2012;27(8):3182–3186. doi:10.1093/ndt/gfs052

19. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24(2):302–308. doi:10.1681/ASN.2012070718

20. Hill NR, Fatoba ST, Oke JL et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One 2016 Jul 6;11(7):e0158765. doi: 10.1371/journal.pone.0158765